Hematologist
CION Cancer Clinics
Philadelphia-positive ALL and TKI treatment | CION Cancer Clinics
Philadelphia-positive ALL is treated with a daily targeted tablet called a tyrosine kinase inhibitor, or TKI, added to steroids and chemotherapy or an antibody drug. It starts as soon as the genetic result is known and usually continues through treatment. This page explains what the chromosome change means, which drugs may be used, when transplant is discussed, and what daily life on a TKI involves. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- How is Philadelphia-positive ALL treated?
- Where does the TKI fit in the treatment plan?
- Which targeted drugs might be used?
- How is it different from Ph-negative ALL?
- What is it like to take a TKI every day?
- What do families often misunderstand about Ph-positive ALL?
- Common questions about Ph-positive ALL treatment
The short answer
How is Philadelphia-positive ALL treated?
Philadelphia-positive (Ph-positive) ALL is treated with a daily targeted tablet called a tyrosine kinase inhibitor (TKI), combined with steroids, chemotherapy or an antibody drug. The tablet is started as soon as the result is known, and it usually continues through every phase of treatment.
What the Philadelphia chromosome is
It is a swap of material between two chromosomes inside the leukaemia cells. The swap joins two genes, called BCR and ABL1, into one faulty gene. That gene sends a constant signal telling the cell to keep growing. It is found in a larger share of adults with ALL than children, and it becomes more common with age. You do not inherit it, and you cannot pass it to your children.
Why this result changes the plan so much
Before TKIs existed, Ph-positive ALL was one of the hardest forms to treat. A TKI blocks the faulty signal directly. That has changed how much chemotherapy many people need, and it has made gentler plans possible for older adults who could not cope with full-intensity chemotherapy.
What your report may say
Reports use several phrases for the same finding: "BCR-ABL1 positive", "t(9;22)", "Ph+" or "Philadelphia chromosome detected". Some reports also name the type of joined gene, such as p190 or p210. Most adults with Ph-positive ALL have the p190 type. The type mostly matters for how the laboratory measures the response later, so keep a copy of this first report safe.
The same chromosome is found in chronic myeloid leukaemia (CML). Some of the tablets are the same, but the disease and the overall plan are not.The pathway
Where does the TKI fit in the treatment plan?
Testing at diagnosis
The bone marrow sample is tested for the BCR-ABL1 change by a genetic test called FISH or PCR. The result often arrives within days, and the tablet is added as soon as it does.
Induction
The TKI is given with steroids and either chemotherapy or, in some centres, an antibody drug instead of most chemotherapy. The aim is remission, meaning no leukaemia can be seen under the microscope.
Measuring the response
A very sensitive test tracks the BCR-ABL1 level in the blood or marrow. This minimal residual disease (MRD) result shapes the next decision.
Transplant or continued TKI
Some people are advised a donor stem cell transplant in first remission. Others with a deep response continue TKI-based treatment. The TKI is often restarted after transplant.
Not sure whether this applies to you?
Ask an oncologistThe medicines
Which targeted drugs might be used?
These are generic names. Your haematologist chooses one for your leukaemia's test results, your heart and your other medicines.
Imatinib
The first TKI, used for many years and widely available in India. It is still used, particularly where cost or access limits the choice.
Dasatinib
A newer, more potent TKI. It reaches the fluid around the brain better than imatinib, which matters in ALL. It can cause fluid around the lungs, so breathlessness should be reported.
Ponatinib
Designed to work against a resistance change called T315I, which older TKIs cannot block. It needs careful checks on blood pressure, the heart and blood vessels.
Not suited to everyone with heart or circulation problems.TKI with an antibody drug
Newer plans pair a TKI with blinatumomab, an antibody that helps immune cells find leukaemia, to use less chemotherapy.
Worth asking
- Is this available and approved for my case?
- What will access involve?
Side by side
How is it different from Ph-negative ALL?
Ph-positive ALL
Ph-negative ALL
A daily TKI tablet is part of the plan from the start
No TKI, unless a similar signal change is found
Response tracked by measuring BCR-ABL1 levels
Response tracked by other MRD markers
Chemotherapy intensity can often be lowered
Chemotherapy intensity set by age and fitness
Transplant discussed depending on MRD response
Transplant discussed mainly for high-risk features
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
At home
What is it like to take a TKI every day?
For most people the tablet becomes part of the daily routine. The difficult part is the combination with other treatment in the early months, not the tablet on its own.
Side effects you may notice
Common ones include tiredness, loose motions, feeling sick, muscle cramps, skin rashes and puffiness around the eyes. Counts can drop. Breathlessness, chest pain or unusual bleeding should be reported the same day. Tell the team early about any effect. Many can be managed without changing the treatment.
Other medicines and food
Several TKIs interact with common medicines, including some antacids, antibiotics, antifungals and herbal products. Grapefruit and some juices can change blood levels too. Show every medicine and supplement to your haematologist or pharmacist, including anything from a local doctor.
Who a particular TKI may not suit
People with heart rhythm problems, previous heart attacks or strokes, poorly controlled blood pressure, liver disease or lung problems may need a different TKI or closer monitoring. Tell the team about every past illness, even one that seems unrelated. It can change which tablet is chosen, and it is much easier to plan around at the start.
Missed tablets
Do not stop, skip or double up on your own. If you have missed tablets, run out, or cannot afford the next supply, call the team. There is often a way to keep treatment going.
Commonly believed
What do families often misunderstand about Ph-positive ALL?
"It is the same as CML, so the treatment is just tablets."
The chromosome change is shared, but ALL is an acute leukaemia and needs a full treatment plan. A tablet on its own is not the plan for most people.
"Once the test turns negative, the tablet can stop."
A negative MRD result is a very good sign, but stopping a TKI is a decision only your haematologist should make. Stopping early can allow the leukaemia to return.
"Ph-positive means a transplant is unavoidable."
It once did for most fit adults. Today the decision depends heavily on how deep the response is, and some people are treated without one.
"A newer tablet is always the stronger choice."
Each TKI has its own side effects. The right one depends on the test results, your heart and your other medicines.
Did you know
This page cannot tell you which TKI you will get or how you will respond. At CION, the haematology team reviews the genetic results and presents the case at a tumour board before the plan is confirmed, then coordinates any transplant or specialised testing with qualified centres.
Questions we are asked
Common questions about Ph-positive ALL treatment
How long will the TKI tablet be needed?
Usually for a long time, often through maintenance and for a period after transplant if one is done. There is no single rule for adults with ALL. Your haematologist decides based on your MRD results and how you tolerate it. Never stop it without their advice.
How do we know if the tablet is working?
Through repeated blood and marrow tests that measure the BCR-ABL1 level. A falling level, and ideally one that becomes undetectable, shows a good response. A rising level may mean the leukaemia is becoming resistant, and the team may test for resistance changes and switch drugs.
What is the T315I mutation on my report?
It is a change in the BCR-ABL1 gene that stops several older TKIs from working. If it is found, your haematologist will talk about drugs designed to overcome it, such as ponatinib, or about other approaches. It is tested when the response is not as expected, not routinely for everyone.
Are TKIs available and affordable in India?
Imatinib and dasatinib are available in India, including as lower-cost generic versions. Newer drugs may be harder to access. Aarogyasri, PM-JAY, CGHS, ECHS, EHS, cashless insurance and patient access programmes can help, but rules change, so check your current cover.
Can an older parent be treated for Ph-positive ALL?
Often yes. Because the TKI does much of the work, many older adults can be offered a gentler plan with less chemotherapy. How much treatment suits them depends on their heart, kidneys and overall fitness rather than age alone. Ask the team what a lower-intensity plan would involve.
Can a TKI be taken during pregnancy?
TKIs can harm an unborn baby, so pregnancy should be avoided while taking one. Use reliable contraception and tell the team straight away if a pregnancy is possible. If you hope to have children later, ask about fertility before treatment begins.
Is spinal chemotherapy still needed with a TKI?
Yes, in almost all plans. ALL can settle in the fluid around the brain and spinal cord, and the tablet alone does not protect that space reliably. Chemotherapy into the spinal fluid through a lumbar puncture is usually given at intervals across treatment.
Does Ph-positive ALL run in families?
No. The Philadelphia chromosome forms inside the leukaemia cells during a person's life. It is not in the rest of the body's cells, and it is not passed to children. Brothers and sisters are not at higher risk, although they may be tested as possible stem cell donors.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Adult Acute Lymphoblastic Leukemia Treatment (PDQ), Patient Version
- Cancer Research UK — Acute lymphoblastic leukaemia (ALL)
- American Cancer Society — Acute Lymphocytic Leukemia (ALL)
- Leukemia & Lymphoma Society — Acute Lymphoblastic Leukemia (ALL)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Acute Lymphoblastic Leukaemia in AdultsThe overview of adult ALL, from diagnosis onwardsAdult ALL Treatment: The Phases ExplainedHow induction, consolidation and maintenance fit togetherMRD-Guided Treatment in Adult ALLHow BCR-ABL1 and other MRD results steer the planWhen Adult ALL Needs a TransplantWhen a transplant is advised in first remission
Talk to us
Report says Philadelphia-positive?
Tell us what has been found so far. CION's haematology team will explain what it means for the plan and help you reach the right specialist. One helpline serves every CION centre.